Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer
Abstract Pancreatic ductal adenocarcinoma (PDAC) responds poorly to systemic treatment, including new immunotherapeutic approaches. Biomarkers are urgently needed for early disease detection, patient stratification for treatment, and response prediction. The role of soluble CD40 (sCD40) is unknown i...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Nature Portfolio
2023-10-01
|
| Ráidu: | npj Precision Oncology |
| Liŋkkat: | https://doi.org/10.1038/s41698-023-00459-9 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|